Maura Gillison, MD
Medical Oncology · Houston, TXNPI 1760436927
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,366 of the $109,456 with a category attached, or 88.0%. 21 manufacturers reported payments, led by Merck at 24.8% of the total. Reporting peaked in 2019 at $35,926 and has fallen 58.7% since, to $14,843 in 2025.
Across 89 payments — averaging $1229.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$27K
- EMD Serono, Inc.$24K
- GSK$10K
- EMD Serono Research & Development Institute, Inc.$7K
- Genmab U.S., Inc.$7K
- Pfizer$5K
- plus $28K from 15 others
Across 66 payments — averaging $74,265 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.7M
- EMD Serono Research & Development Institute, Inc.$354K
- Seagen Inc.$285K
- E.r. Squibb & Sons, L.L.C.$219K
- AbbVie$132K
- Genentech, Inc.$105K
- plus $71K from 2 others
What the payments were for
- Consulting fees$96,36688%
- Speaking & faculty fees$1,9002%
- Travel & lodging$9,2928%
- Food & beverage$1,8982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $27,175 |
| EMD Serono, Inc. | 8 | $24,131 |
| GSK | 8 | $10,171 |
| EMD Serono Research & Development Institute, Inc. | 3 | $7,425 |
| Genmab U.S., Inc. | 8 | $6,968 |
| Pfizer | 4 | $5,359 |
| Bayer | 11 | $4,496 |
| Roche Molecular Systems, Inc. | 4 | $3,639 |
| Roche Diagnostics Corporation | 1 | $3,000 |
| Gilead | 1 | $2,850 |
| Coherus Oncology, Inc. | 1 | $2,363 |
| Day One Biopharmaceuticals | 1 | $2,280 |
| Eisai Inc. | 1 | $2,040 |
| Janssen Scientific Affairs, LLC | 1 | $1,763 |
| B. Braun Medical UK Ltd. | 2 | $1,666 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,360 |
| AbbVie | 1 | $1,088 |
| Seagen Inc. | 1 | $994 |
| Biontech SE | 1 | $600 |
| Regeneron | 1 | $60 |
| Ventana Medical Systems, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$6,768
- Vitrakvi$4,221
- MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT$3,639
- TD BenchMark IHC/ISH and Special Stains Reagents$3,000
- LENVIMA$2,040
- RYBREVANT$1,763
How this compares
$109,456 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.